Other recruiting clinical trials include the ICOS inhibitor vopratelimab in combination with ipilimumab in patients with advanced and/or refractory NSCLC (NCT0398936) after prior aPD‐1/anti‐PD‐L1 therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.